Horsham, PA (Vocus) July 30, 2008
The Drug Information Association (DIA) and the American Association of Pharmaceutical Scientists (AAPS) will co-sponsor Immunogenicity of Therapeutic Proteins (September 10 -12; Bethesda, MD).
Discussion topics will include:
“Industry practices in immunogenicity assessment are becoming more unified though challenges still exist in terms of technology and reduction to practice,” says Program Chair Steven J. Swanson, PhD, Executive Director, Medical Sciences, Clinical Immunology Department, Amgen, Inc. “This conference will review key aspects of assay development and validation as well as discuss challenges in implementation of these assays, data interpretation, and relevance to clinical outcomes.”
About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, and Mumbai, India, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.
About the American Association of Pharmaceutical Scientists (AAPS):
AAPS is a professional, scientific society of more than 13,500 members employed in industry, academia, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to public health. AAPS offers timely scientific programs, on-going education, information resources, opportunities for networking, and professional development.
Joe.Krasowski @ diahome.org